Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
Huawei claims it has developed its own operating system for smartphones and laptops for "extenuating circumstances."Technologyread more
Trump's threat, posted on Twitter, comes amid rising international tensions in the Middle East as the U.S. has dispatched a carrier strike group and bomber task force to the...Politicsread more
Prime Minister Narendra Modi and his Bharatiya Janata Party are set to form the new government again, exit polls from India's month-long parliamentary elections show. But past...Electionsread more
The latest crisis in the uneasy French-German relationship was accelerated by Trump's decision to stop Germany's comfortable and decades-old free-riding on trade and security...Europe Politicsread more
While some fans of the long-running "Game of Thrones" felt satisfied by the show's final bow, others were quick to express their displeasure with how events unfolded.Entertainmentread more
Stocks in Asia were mostly higher on Monday amid rising tensions between the U.S. and China.Asia Marketsread more
Current geopolitical tensions are making it harder and harder for oil-producing nations to make decisions that will help stabilize crude prices, Russian Energy Minister...Oilread more
Russian Energy Minister Alexander Novak said there were different options available for OPEC and its oil-producing allies in the second half of 2019, including a possible...Oilread more
The Australian Electoral Commission (AEC) on Monday said Morrison's coalition has won 76 seats in Australia's parliament, which is comprised of 151 elected lawmakers.Electionsread more
U.S. President Donald Trump said his tariffs on Chinese goods are causing companies to move production out of China to Vietnam and other countries in Asia, and added that any...World Politicsread more
Shares of Amgen fell 3 percent in extended trading after the company issued weak 2019 guidance, which overshadowed its better-than-expected fourth-quarter earnings, after the market close on Tuesday.
The biotech company said it expects adjusted 2019 earnings per share between $13.10 and $14.30. That range is well below Wall Street projections for full-year earnings of $14.61 per share, according to a Refinitiv consensus estimate.
For 2019, Amgen said it expects revenue between $21.8 billion and $22.9 billion. That range is also below Wall Street's estimate for revenue of $22.91 billion.
Amgen's 2019 outlook represents a year-over-year decline in both earnings and revenue. For 2018, the company reported adjusted earnings of $14.40 per share on revenue of $23.75 billion.
The biotech company, however, reported fourth-quarter earnings and revenue that topped analyst expectations.
Here's how the company did compared with what Wall Street expected:
In the year-ago quarter, Amgen reported adjusted earnings of $2.89 per share on $5.80 billion in revenue.
Amgen's second-largest drug, Neulasta, posted fourth-quarter sales of $1.17 billion, topping expectations for $1 billion in sales. The company's largest drug, Enbrel, also posted better-than-expected sales of $1.32 billion, compared with projections of $1.30 billion.
Shares of Amgen have fallen about 3 percent over the past year.